With nine drugs expected to lose their patents between 2011 and 2016, the US Cholesterol Lowering Agents (Dyslipidemia) Market currently stands at the edge of a major patent cliff. IMARC Group, one of the world’s leading research and advisory firms, expects in its new report” US Cholesterol Lowering Agents Market Report & Forecast: On the Edge of a Patent Cliff” that despite a strong performance of Crestor (Rosuvatation), the avalanche of patent expiries and a thin drug pipeline will erode this market of sales worth more than US$ 8.7 billion in the next six years.
This report provides an analytical and statistical insight into the US Cholesterol Lowering agents Market. The study that has been undertaken using both desk-based as well as qualitative primary research has analyzed the following aspects of this market:
Key Aspects Analyzed:
Understanding the Epidemiology of Dyslipidemia in the US:
Focus of the Analysis:
Comprehensive Evaluation of the US Cholesterol Lowering Agents Market:
Classes Covered: Statins, Fixed Dose Combinations, Ion Exchange Resins, Fibrates, Other Cholesterol Triglyceride Regulators, Omega-3 Acid Ethyl Esters and CETP Inhibitors
Molecules Covered: Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin, Fluvastatin, Lovastatin, Pitavastatin, Ezetimibe/Simvastatin, ER Niacin/Simvastatin, Atorvastatin/Amlodipine, ER Naicin/Laropiprant, Ezetimibe/Atorvastatin, ER Niacin/Laropiprant/Simvastatin, Colesevelam, Cholestyramine, Colestipol, Fenofibrate, Fenofibric Acid, Gemfibrozil, Dalcetrapib, Anacetrapib
Focus of the Analysis for Each Class & Molecule:
Comprehensive Evaluation of Generic Opportunities in the US Cholesterol Lowering Agents Market:
Information Sources:
Information has been sourced from both primary and secondary sources: